Taken together, several therapies are available to target HER2; however, a huge number of patients still die of HER2+ breast cancer, thus calling for the identification of new agents and approaches to be used alone or in combination with existing treatments [17,18]. The gene discussed is ERBB2; the disease is breast cancer.